Literature DB >> 11983253

Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.

Weidong Xu1, Regina Hofmann-Lehmann, Harold M McClure, Ruth M Ruprecht.   

Abstract

Passive immunization with synergistic combinations of human monoclonal antibodies (mAbs) directed against conserved epitopes of the human immunodeficiency virus (HIV) envelope completely protected 13 out of 16 rhesus monkeys challenged intravenously or orally with chimeric simian-human immunodeficiency virus (SHIV) strains; partial protection was seen in another two. A high degree of protection was seen among orally challenged neonates. Thus, we propose that passive immunization with synergistic combinations of neutralizing human mAbs may be effective in preventing maternal HIV transmission when given as post-exposure prophylaxis at birth and as prophylaxis against milk-borne transmission. Because we only used mAbs with well-defined epitope specificities, our studies also yield key information for designing AIDS vaccines: the correlates of immune protection. Vaccine strategies that can evoke antibody responses to epitopes recognized by the mAbs used in our primate studies could be important components of successful AIDS vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11983253     DOI: 10.1016/s0264-410x(02)00077-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Non-Antiretroviral Microbicides for HIV Prevention.

Authors:  Yanille Scott; Charlene S Dezzutti
Journal:  AIDS Rev       Date:  2016 Jul-Sep       Impact factor: 2.500

2.  Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses.

Authors:  Rajesh Abraham Jacob; Fatima Abrahams; Marcel Tongo; Michael Schomaker; Paul Roux; Eitel Mpoudi Ngole; Wendy A Burgers; Jeffrey R Dorfman
Journal:  J Virol       Date:  2012-05-09       Impact factor: 5.103

3.  Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.

Authors:  Royce A Wilkinson; Chayne Piscitelli; Martin Teintze; Lisa A Cavacini; Marshall R Posner; C Martin Lawrence
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120.

Authors:  H W Wang; D Cole; W Z Jiang; H T Jin; N Fu; Z L Chen; N Y Jin
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 5.  Identifying and characterizing recently transmitted viruses.

Authors:  Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2010-07       Impact factor: 4.283

6.  A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS.

Authors:  Dinesh K Singh; Zhenqian Liu; Darlene Sheffer; Glenn A Mackay; Marilyn Smith; Sukhbir Dhillon; Ramakrishna Hegde; Fenglan Jia; Istvan Adany; Opendra Narayan
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

Authors:  Xiaoping Liang; Danilo R Casimiro; William A Schleif; Fubao Wang; Mary-Ellen Davies; Zhi-Qiang Zhang; Tong-Ming Fu; Adam C Finnefrock; Larry Handt; Michael P Citron; Gwendolyn Heidecker; Aimin Tang; Minchun Chen; Keith A Wilson; Lori Gabryelski; Michael McElhaugh; Anthony Carella; Cheryl Moyer; Lingyi Huang; Salvatore Vitelli; Deepa Patel; Jing Lin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms.

Authors:  Kyle J Nakamura; Johannes S Gach; Laura Jones; Katherine Semrau; Jan Walter; Frederic Bibollet-Ruche; Julie M Decker; Laura Heath; William D Decker; Moses Sinkala; Chipepo Kankasa; Donald Thea; James Mullins; Louise Kuhn; Michael B Zwick; Grace M Aldrovandi
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

9.  Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge.

Authors:  Katja Klein; Ronald S Veazey; Ranjit Warrier; Peter Hraber; Lara A Doyle-Meyers; Viviana Buffa; Hua-Xin Liao; Barton F Haynes; George M Shaw; Robin J Shattock
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

10.  Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Authors:  Georgia D Tomaras; Nicole L Yates; Pinghuang Liu; Li Qin; Genevieve G Fouda; Leslie L Chavez; Allan C Decamp; Robert J Parks; Vicki C Ashley; Judith T Lucas; Myron Cohen; Joseph Eron; Charles B Hicks; Hua-Xin Liao; Steven G Self; Gary Landucci; Donald N Forthal; Kent J Weinhold; Brandon F Keele; Beatrice H Hahn; Michael L Greenberg; Lynn Morris; Salim S Abdool Karim; William A Blattner; David C Montefiori; George M Shaw; Alan S Perelson; Barton F Haynes
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.